- In April 2024, Teva Pharmaceutical Industries Ltd. announced the discontinuation of its Phase III ENFORCE trial for fremanezumab in treating chronic cluster headaches. The decision followed a futility analysis indicating the primary endpoint was unlikely to be met. Despite this, Teva continues to explore fremanezumab's potential in episodic cluster headache and migraine treatments, reflecting the company's dedication to advancing CGRP-targeting therapies
- In March 2024, a real-world study conducted in Brazil demonstrated the effectiveness of galcanezumab in reducing the frequency of cluster headache attacks among patients. The study's findings support the use of galcanezumab as a viable prophylactic treatment option, highlighting its role in improving patient outcomes in clinical practice
- In September 2023, Eli Lilly and Company received FDA approval for Emgality (galcanezumab-gnlm) as the first and only medication specifically indicated for the treatment of episodic cluster headache. This approval underscores the company's commitment to addressing unmet needs in neurological disorders by providing targeted therapies that reduce the frequency of debilitating headache attacks
- In 2023, a clinical trial led by the George Institute for Global Health in Sydney explored the use of psilocybin, a psychedelic compound found in mushrooms, as a potential treatment for cluster headaches. The study aims to assess the feasibility and effectiveness of psilocybin in alleviating the intensity and frequency of cluster headache attacks, reflecting a growing interest in alternative therapies for this debilitating condition
- In May 2021, Unity HA, a U.S.-based medical device company, launched the Pulsante SPG Microstimulator System for treating acute pain associated with chronic cluster headaches. This FDA-approved implantable neurostimulation device represents an innovative approach to pain management, offering a targeted and minimally invasive solution for patients suffering from severe headache disorders
